News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PrognosDx Health Announces Publication of Novel Epigenetic Study in Journal of Clinical Oncology



2/10/2010 10:13:28 AM

Bookmark and Share

PALO ALTO, Calif.--(BUSINESS WIRE)--PrognosDx Health, Inc. announced today that in an independent research study published online in the Journal of Clinical Oncology, cellular levels of histone modifications define previously unrecognized subsets of patients with pancreatic cancer with distinct epigenetic phenotypes and clinical outcomes. Histone modifications represent novel prognostic and predictive biomarkers that could inform clinical decisions, including use of fluorouracil (5-FU) chemotherapy.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES